33.21
Precedente Chiudi:
$33.92
Aprire:
$33.84
Volume 24 ore:
916.60K
Relative Volume:
0.59
Capitalizzazione di mercato:
$4.00B
Reddito:
$10.12M
Utile/perdita netta:
$-280.49M
Rapporto P/E:
-11.49
EPS:
-2.89
Flusso di cassa netto:
$-188.51M
1 W Prestazione:
-2.44%
1M Prestazione:
+11.18%
6M Prestazione:
+11.93%
1 anno Prestazione:
-25.62%
Avidity Biosciences Inc Stock (RNA) Company Profile
Nome
Avidity Biosciences Inc
Settore
Industria
Telefono
858-401-7900
Indirizzo
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Confronta RNA con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
RNA
Avidity Biosciences Inc
|
33.21 | 4.04B | 10.12M | -280.49M | -188.51M | -2.89 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-07-10 | Ripresa | Goldman | Buy |
2025-06-24 | Iniziato | Bernstein | Outperform |
2025-06-17 | Iniziato | Wolfe Research | Outperform |
2025-06-11 | Iniziato | Raymond James | Strong Buy |
2025-03-13 | Iniziato | Citigroup | Buy |
2025-03-12 | Iniziato | BMO Capital Markets | Outperform |
2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
2024-12-20 | Iniziato | H.C. Wainwright | Buy |
2024-11-26 | Iniziato | RBC Capital Mkts | Outperform |
2024-09-24 | Iniziato | Goldman | Buy |
2024-08-28 | Iniziato | Barclays | Overweight |
2024-05-03 | Iniziato | BofA Securities | Buy |
2024-03-14 | Iniziato | Cantor Fitzgerald | Overweight |
2023-05-22 | Aggiornamento | Evercore ISI | In-line → Outperform |
2023-03-31 | Downgrade | Evercore ISI | Outperform → In-line |
2022-07-20 | Iniziato | Chardan Capital Markets | Buy |
2022-07-12 | Iniziato | Raymond James | Strong Buy |
2021-09-07 | Iniziato | Evercore ISI | Outperform |
2021-06-17 | Iniziato | Needham | Buy |
2021-04-26 | Ripresa | Credit Suisse | Outperform |
2020-07-07 | Iniziato | Cowen | Outperform |
2020-07-07 | Iniziato | Credit Suisse | Outperform |
2020-07-07 | Iniziato | SVB Leerink | Outperform |
2020-07-07 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Avidity Biosciences Inc Borsa (RNA) Ultime notizie
How Avidity Biosciences Inc. stock reacts to Fed policy changesFree Smart Trading Workshop - jammulinksnews.com
Is Avidity Biosciences Inc. a good long term investmentAccelerated wealth building - Autocar Professional
Avidity Biosciences shares climb after FDA grants Breakthrough Therapy designation - MSN
Avidity Biosciences shares rise 1.80% premarket after receiving FDA Breakthrough Therapy designation for DMD treatment. - AInvest
What drives Avidity Biosciences Inc. stock priceOverwhelming profit margins - jammulinksnews.com
Avidity Biosciences Gains FDA Breakthrough Therapy Designation - TipRanks
Why Avidity Biosciences Inc. stock attracts strong analyst attentionFree Stock Movement Tracking - beatles.ru
Avidity gets FDA breakthrough therapy status for DMD treatment - Seeking Alpha
FDA grants breakthrough therapy status to Avidity’s DMD drug By Investing.com - Investing.com Canada
Avidity Biosciences stock rises after FDA grants Breakthrough Therapy status - Investing.com
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping - PR Newswire
What analysts say about Avidity Biosciences Inc. stockOutstanding capital appreciation - jammulinksnews.com
Avidity Biosciences Inc. Stock Analysis and ForecastExtraordinary market timing - jammulinksnews.com
(RNA) On The My Stocks Page - news.stocktradersdaily.com
Avidity Biosciences: Three Accelerated Approval Shots Feels Excessive (NASDAQ:RNA) - Seeking Alpha
RNA News Today | Why did Avidity Biosciences stock drop today? - MarketBeat
Goldman Sachs resumes coverage on Avidity Biosciences stock with Buy rating - Investing.com Canada
Avidity Biosciences, Inc Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Avidity Biosciences, Inc Rings the Opening Bell - Nasdaq
Avidity Biosciences’ SWOT analysis: innovative muscle therapy stock faces key milestones - Investing.com
Avidity Biosciences, Inc.(NasdaqGM: RNA) added to Russell 3000E Value Index - MarketScreener
(RNA) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Avidity Biosciences’ Promising Phase 3 Study on FSHD Treatment: Market Implications - TipRanks
Avidity Biosciences’ SWOT analysis: innovative RNA firm eyes 3-drug launch by 2027 - Investing.com
Wolfe Research Initiates Coverage on Avidity Biosciences (RNA) with 'Outperform' Rating | RNA Stock News - GuruFocus
Avidity Biosciences (RNA) Receives Outperform Rating Amid Biotec - GuruFocus
Why Avidity Biosciences Shares Are Under the Spotlight - TipRanks
Wolfe Research Initiates Coverage on Avidity Biosciences With Outperform Rating, $55 Price Target - MarketScreener
Avidity Biosciences (RNA) Receives Outperform Rating Amid Biotech Advancements | RNA Stock News - GuruFocus
(RNA) Proactive Strategies - news.stocktradersdaily.com
Avidity Biosciences (RNA) Receives Outperform Rating from Wolfe Research | RNA Stock News - GuruFocus
The week in pharma: action, reaction and insight – week to June 13 - The Pharma Letter
Avidity Biosciences’ SWOT analysis: innovative RNA tech targets rare disease stock potential - Investing.com Australia
Avidity Biosciences’ SWOT analysis: innovative RNA tech targets rare disease stock potential By Investing.com - Investing.com South Africa
Avidity Biosciences chief scientific officer sells $657,694 in stock - Investing.com India
Avidity Biosciences, Inc. (RNA) Initiated with a Strong Buy at Raymond James - MSN
Avidity Biosciences chief scientific officer sells $657,694 in stock By Investing.com - Investing.com South Africa
Avidity Biosciences Inc Azioni (RNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):